Report Overview

Germanys Migraine Therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.

Migraine accounts for a great part of the healthcare impact of headaches in Germany. Approximately 60% of headache sufferers reported severe headaches, 30% of which were migraineurs.

In Germany, according to various researches it was found out that prevalence of all headache types was highest in young and middle-aged adults up to age 50 years and declined thereafter. While the prevalence of all migraine, including migraine with visual aura, decreased with age, the proportion of migraine with visual aura to migraine without aura increased with advancing age. Migraine was 3 times more common in women than in men.



Market Drivers

The migraine therapeutics market is driven by the increase in the number of patients suffering from migraines. In addition, the rising advances in migraine therapeutics are anticipated to boost the growth of the migraine therapeutics market. Enhancements in the reimbursement policies associated with the medications and increasing awareness in people by organizing programs are favorable factors to the market growth. The growing R&D investments are further expected to support the market during the forecast period.

Approval of the new drugs manufactured to treat migraine headaches, the presence of key players like Pfizer, Eli Lilly, and many more are also driving the market. Moreover, the FDA approvals of novel drugs by the key players in the market accelerate the region's growth.